Verve Therapeutics Operating Income

Verve Therapeutics (VERV) currently reports a operating income of $-210M as of March 2025. That compares with $-220M in the prior-year period — up 6.0% year over year. Use the charts on this page to explore Verve Therapeutics's operating income history and peer comparisons.

Verve Therapeutics's operating income increased from $-220M to $-210M — a 6.0% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Verve Therapeutics reported $-210M in operating income as of March 2025. That compares with $-220M in the prior-year period — up 6.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-210M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Verve Therapeutics, and consider following VERV for alerts when major investors trade the stock.

Verve Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-210M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VERV with unrelated industries.